Intellia Therapeutics
NTLA
85 hedge funds and large institutions have $439M invested in Intellia Therapeutics in 2017 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 34 increasing their positions, 17 reducing their positions, and 13 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 17
63% more capital invested
Capital invested by funds: $269M → $439M (+$170M)
15% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 13
2.29% more ownership
Funds ownership: 46.66% → 48.95% (+2.3%)
0% more funds holding
Funds holding: 85 → 85 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
58% less call options, than puts
Call options by funds: $1.55M | Put options by funds: $3.71M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GTP
Global Thematic Partners
New York
|
+$9.46M |
| 2 |
GC
GMT Capital
Atlanta,
Georgia
|
+$6.23M |
| 3 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$3.72M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$2.18M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$904K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AVAI
Atlas Venture Associates IX
Boston,
Massachusetts
|
-$2.83M |
| 2 |
AG
Artal Group
Luxembourg
|
-$1.41M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$1.19M |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$1.13M |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
-$918K |
NTLA Hedge Fund Activity: Q3 2017 in Review
85 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Intellia Therapeutics (NTLA) for Q3 2017, worth a combined $439M — up 63% from $269M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new NTLA positions and 13 closed out — a net gain of 2 holders — while 34 added to existing stakes and 17 trimmed.
The largest buyer was Global Thematic Partners, opening a new position worth an estimated $9.46M. The largest seller was Atlas Venture Associates IX, cutting an estimated $2.83M.
- 85 institutional investors held Intellia Therapeutics (NTLA) as of Q3 2017, unchanged from Q2 2017.
- Funds reported $439M of Intellia Therapeutics stock for Q3 2017, up 63% quarter-over-quarter.
- 15 funds opened new Intellia Therapeutics positions in Q3 2017 and 13 closed out, a net change of +2 holders.
- The largest Intellia Therapeutics buyer in Q3 2017 was Global Thematic Partners, an estimated $9.46M added.
- The largest Intellia Therapeutics seller in Q3 2017 was Atlas Venture Associates IX, an estimated $2.83M sold.
Based on aggregated 13F filings for Q3 2017.